on The Rainwater Charitable Foundation
The Rainwater Charitable Foundation Supports Neurodegenerative Drug Research
The Rainwater Charitable Foundation has announced grants totaling over $1 million for three research projects targeting tau protein in neurodegenerative diseases. This funding, part of the Sprint to Lead program, aims to advance preclinical drug candidates by focusing on tau-driven conditions such as progressive supranuclear palsy and other tauopathies.
Dr. Timothy Miller, Dr. Neil Vasdev, and Dr. Markus Zweckstetter have received $350,000 each to support their innovative projects. Dr. Miller is working with antisense oligonucleotides to balance tau isoforms, while Dr. Vasdev's team is developing tau degraders to eliminate harmful tau. Dr. Zweckstetter focuses on small molecules to prevent pathological tau aggregation.
These efforts are part of a larger initiative to translate scientific discoveries into therapies that could offer new hope for patients suffering from these debilitating disorders.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Rainwater Charitable Foundation news